3-Step treatment efficient for small pupils

Article

According to recently published data, a 3-step treatment protocol is an efficient way to ensure good safety margins for patients with pupils smaller than 5.5 mm

According to recently published data, a 3-step treatment protocol is an efficient way to ensure good safety margins for patients with pupils smaller than 5.5 mm undergoing femtosecond laser-assisted cataract surgery.

The study, led by Dr Ina Conrad-Hengerer (Center for Vision Science, Ruhr University Eye Hospital, Bochum, Germany), examined eyes with an intraoperative pupil size smaller than 5.5 mm to evaluate the efficacy of a 3-step treatment to achieve larger pupil sizes before femtosecond laser-assisted cataract surgery. This 3-step process consisted of initially administering intracameral epinephrine solution, then using additional viscomydriasis and thirdly implantation of a Malyugin ring pupil expander.

Out of 850 eyes that were scheduled to receive cataract surgery, 40 underwent the sequential treatments for pupil expansion. Of this group, 7% only required the first step to achieve a pupil size larger than 5.5 mm, 25% required additional voscomydriasis and 68% needed the pupil expander as well. The team found that the most frequent comorbidities were pseudoexfoliation of the lens capsule (30%) and intraoperative floppy-iris syndrome (12.5%).

Based on this study, it was deemed that the 3-step treatment allowed an increased efficiency and safety of femtosecond laser-assisted cataract surgery in eyes with a small pre-op pupil size.

For more detailed information please view the abstract from the Journal of Cataract & Refractive Surgery.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.